17 unchanged sentences
Rule 10b5-1 Trading Arrangements
−Removed: The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the fourth quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
−Removed: Name and Title Action Adoption/ Termination Date
−Removed: Scheduled Expiration Date of Trading Plan (1)
−Removed: Maximum Shares Subject to Trading Plan
−Removed: Terrance Coyne
−Removed: Executive Vice President & Chief Financial Officer
−Removed: November 22, 2023 October 17, 2024 480,000
−Removed: Marshall Urist
−Removed: Executive Vice President, Research and Investments
−Removed: December 20, 2023 December 30, 2024 46,667
−Removed: (1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
+Added: During the fourth quarter of 2024, no director or Section 16 officer adopted , modified or terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements.
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
26 unchanged sentences
Period End Date Filed or Furnished Herewith
+Added: 2.1 Membership Interests Purchase Agreement, dated January 10, 2025, among Royalty Pharma, LLC, RP Management, LLC, the Sellers named therein and Royalty Pharma Holdings Ltd.
+Added: 2.1 1/10/2025
3.1 Articles of Association of Royalty Pharma plc
7 unchanged sentences
10-Q 10.1 11/08/2022
−Removed: 10.2 Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Ltd, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP
+Added: 10.2 Exchange Agreement dated December 31, 2024, among the Company, RP Holdings, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP, RPI US Feeder 2019, LP, RPI International Feeder 2019, LP, RPI EPA Holdings, LP and RPI EPA Vehicle LLC
8-K 10.1 12/31/2024
3 unchanged sentences
S-1/A 10.5 6/2/2020
−Removed: 10.5† Director Appointment Agreement, dated June 9, 2020, between the Company and Mr.
−Removed: Germano Giuliani
−Removed: S-1/A 10.6 6/11/2020
10.6# Amended and Restated Purchase and Sale Agreement, dated November 14, 2014, with the Cystic Fibrosis Foundation Therapeutics Incorporated
40 unchanged sentences
4, dated as of January 24, 2024, among Royalty Pharma plc, Royalty Pharma Holdings Ltd., Bank of America, N.A., as Administrative Agent, the other parties thereto, and the lenders and issuing banks from time to time party thereto
+Added: 10.21 2/15/2024
+Added: 10.22 Third S upplemental Indenture, dated as of June 10, 2024, Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee
+Added: 8-K 4.2 6/10/2024
+Added: 19.1 Insider Trading Policy
21.1 Subsidiaries of the Registrant
1 unchanged sentence
24.1 Power of Attorney (reference is made to the signature page hereto) x
−Removed: 31.1 Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: 31.2 Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: 32* Certifications of Chief Executive Office and Chief Financial Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
+Added: 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
+Added: 32* Certifications of Chief Executive Office r and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act
97.1 Financial Restatement Compensation Recoupment Policy
−Removed: 101.INS XBRL Taxonomy Extension Instance Document
+Added: 10-K 97.1 2/15/2024
+Added: 101.INS XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH XBRL Taxonomy Extension Schema Document
3 unchanged sentences
101.PRE XBRL Taxonomy Extension Presentation Linkbase
−Removed: 104 Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101) x
+Added: 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
† Management contract or compensatory plan or arrangement.
4 unchanged sentences
ROYALTY PHARMA PLC
−Removed: February 15, 2024 /s/ Pablo Legorreta
+Added: February 12, 2025
+Added: /s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer
−Removed: February 15, 2024 /s/ Terrance Coyne
+Added: February 12, 2025
+Added: /s/ Terrance Coyne
Terrance Coyne
20 unchanged sentences
Henry Fernandez
−Removed: Germano Giuliani Director February 15, 2024
−Removed: Germano Giuliani
/s/ David Hodgson Director February 12, 2025
3 unchanged sentences
Gregory Norden
−Removed: /s/ Rory Riggs Director February 15, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.